Systematic review of effectiveness of oral sirolimus after bare-metal stenting of coronary arteries for prevention of in-stent restenosis

American Journal of Cardiology

Volumn 112, Issue 9, 2013, Pages 1322-1327

  Dasari, Tarun W ^a   Patel, Bhavin ^a   Saucedo, Jorge F ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ANGIOGRAPHY; BARE METAL STENT; CARDIOVASCULAR DISEASE; CORONARY ARTERY; DATA BASE; EMBASE; HEALTH CARE COST; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; MEDLINE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY VESSELS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; SIROLIMUS; STENTS;

EID: 84885950138     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.05.074     Document Type: Review

References (29)

1. K.A. Martin, E.M. Rzucidlo, B.L. Merenick, D.C. Fingar, D.J. Brown, R.J. Wagner, and R.J. Powell The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation Am J Physiol Cell Physiol 286 2004 C507 C517
2. R. Fattori, and T. Piva Drug-eluting stents in vascular intervention Lancet 361 2003 247 249
3. G.G. Stefanini, and D.R. Holmes Jr. Drug-eluting coronary-artery stents N Engl J Med 368 2013 254 265
4. F.S. Brito Jr., W.C. Rosa, J.A. Arruda, H. Tedesco, J.O. Pestana, and V.C. Lima Efficacy and safety of oral sirolimus to inhibit in-stent intimal hyperplasia Catheter Cardiovasc Interv 64 2005 413 418
5. W.K. Laskey, C.W. Yancy, and W.H. Maisel Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7-8, 2006 Circulation 115 2007 2352 2357
6. H. Kaneda, T. Koizumi, J. Ako, M. Terashima, Y. Morino, Y. Honda, P.G. Yock, M.B. Leon, J.W. Moses, and P.J. Fitzgerald Impact of intravascular ultrasound lesion characteristics on neointimal hyperplasia following sirolimus-eluting stent implantation Am J Cardiol 96 2005 1237 1241
7. A. Farb, M. John, E. Acampado, F.D. Kolodgie, M.F. Prescott, and R. Virmani Oral everolimus inhibits in-stent neointimal growth Circulation 106 2002 2379 2384
8. M. Poon, S.O. Marx, R. Gallo, J.J. Badimon, M.B. Taubman, and A.R. Marks Rapamycin inhibits vascular smooth muscle cell migration J Clin Invest 98 1996 2277 2283
9. A.J. Chaves, A.G. Sousa, L.A. Mattos, A. Abizaid, F. Feres, R. Staico, M. Centemero, L.F. Tanajura, A.C. Abizaid, A. Rodrigues, A. Paes, G.S. Mintz, and J.E. Sousa Pilot study with an intensified oral sirolimus regimen for the prevention of in-stent restenosis in de novo lesions: a serial intravascular ultrasound study Catheter Cardiovasc Interv 66 2005 535 540
10. E. Guarda, E. Marchant, A. Fajuri, A. Martinez, S. Moran, M. Mendez, P. Uriarte, E. Valenzuela, and R. Lazen Oral rapamycin to prevent human coronary stent restenosis: a pilot study Am Heart J 148 2004 e9
11. A.E. Rodriguez, M.R. Alemparte, C.F. Vigo, C.F. Pereira, C. Llaurado, M. Russo, R. Virmani, and J.A. Ambrose Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial) J Invasive Cardiol 15 2003 581 584
12. P.S. Brara, M. Moussavian, M.A. Grise, J.P. Reilly, M. Fernandez, R.A. Schatz, and P.S. Teirstein Pilot trial of oral rapamycin for recalcitrant restenosis Circulation 107 2003 1722 1724
13. A.E. Rodriguez, M. Rodriguez Alemparte, C.F. Vigo, C. Fernandez Pereira, C. Llaurado, D. Vetcher, A. Pocovi, and J. Ambrose Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial) Heart 91 2005 1433 1437
14. R. Waksman, A.E. Ajani, A.D. Pichard, R. Torguson, E. Pinnow, D. Canos, L.F. Satler, K.M. Kent, P. Kuchulakanti, C. Pappas, L. Gambone, N. Weissman, M.C. Abbott, and J. Lindsay Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study J Am Coll Cardiol 44 2004 1386 1392
15. J. Hausleiter, A. Kastrati, J. Mehilli, M. Vogeser, D. Zohlnhofer, H. Schuhlen, C. Goos, J. Pache, F. Dotzer, G. Pogatsa-Murray, J. Dirschinger, U. Heemann, and A. Schomig Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial Circulation 110 2004 790 795
16. A.E. Rodriguez, C. Fernandez Pereira, and M. Rodriguez Alemparte Oral rapamycin in the treatment of diffuse proliferative in-stent restenosis in a patient with small reference vessel J Invasive Cardiol 15 2003 515 518
17. A.E. Rodriguez, A. Maree, S. Tarragona, C. Fernandez-Pereira, O. Santaera, A.M. Rodriguez Granillo, G.A. Rodriguez-Granillo, M. Russo-Felssen, N. Kukreja, D. Antoniucci, I.F. Palacios, and P.W. Serruys Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study EuroIntervention 5 2009 255 264
18. A.E. Rodriguez, A.M. Rodriguez-Granillo, D. Antoniucci, J. Mieres, C. Fernandez-Pereira, G.A. Rodriguez-Granillo, O. Santaera, B. Rubilar, I.F. Palacios, and P.W. Serruys Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial Catheter Cardiovasc Interv 80 2012 385 394
19. C. Cernigliaro, M. Sansa, G. Vitrella, A. Verde, A.S. Bongo, L. Giuliani, and E. Novelli Preventing restenosis after implantation of bare stents with oral rapamycin: a randomized angiographic and intravascular ultrasound study with a 5-year clinical follow-up Cardiology 115 2010 77 86
20. A.E. Rodriguez, J.F. Granada, M. Rodriguez-Alemparte, C.F. Vigo, J. Delgado, C. Fernandez-Pereira, A. Pocovi, A.M. Rodriguez-Granillo, D. Schulz, A.E. Raizner, I. Palacios, W. O'Neill, G.L. Kaluza, and G. Stone Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study J Am Coll Cardiol 47 2006 1522 1529
21. S. Stojkovic, M. Ostojic, M. Nedeljkovic, G. Stankovic, B. Beleslin, V. Vukcevic, D. Orlic, A. Arandjelovic, J. Kostic, M. Dikic, and M. Tomasevic Systemic rapamycin without loading dose for restenosis prevention after coronary bare metal stent implantation Catheter Cardiovasc Interv 75 2010 317 325
22. T.J. Ryan, D.P. Faxon, R.M. Gunnar, J.W. Kennedy, S.B. King 3rd, F.D. Loop, K.L. Peterson, T.J. Reeves, D.O. Williams, and W.L. Winters Jr. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty) Circulation 78 1988 486 502
23. M.N. Babapulle, L. Joseph, P. Belisle, J.M. Brophy, and M.J. Eisenberg A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents Lancet 364 2004 583 591
24. G.W. Stone, J.W. Moses, S.G. Ellis, J. Schofer, K.D. Dawkins, M.C. Morice, A. Colombo, E. Schampaert, E. Grube, A.J. Kirtane, D.E. Cutlip, M. Fahy, S.J. Pocock, R. Mehran, and M.B. Leon Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 356 2007 998 1008
25. A. Keogh, M. Richardson, P. Ruygrok, P. Spratt, A. Galbraith, G. O'Driscoll, P. Macdonald, D. Esmore, D. Muller, and S. Faddy Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial Circulation 110 2004 2694 2700
26. H.J. Eisen, E.M. Tuzcu, R. Dorent, J. Kobashigawa, D. Mancini, H.A. Valantine-von Kaeppler, R.C. Starling, K. Sorensen, M. Hummel, J.M. Lind, K.H. Abeywickrama, and P. Bernhardt Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients N Engl J Med 349 2003 847 858
27. T.W. Dasari, T.A. Hennebry, E.B. Hanna, and J.F. Saucedo Drug eluting versus bare metal stents in cardiac allograft vasculopathy: a systematic review of literature Catheter Cardiovasc Interv 77 2011 962 969
28. L. Raber, M. Magro, G.G. Stefanini, B. Kalesan, R.T. van Domburg, Y. Onuma, P. Wenaweser, J. Daemen, B. Meier, P. Juni, P.W. Serruys, and S. Windecker Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study Circulation 125 2012 1110 1121
29. G. Barone-Rochette, J. Machecourt, G. Vanzetto, A. Foote, J.L. Quesada, C. Castelli, N. Danchin, and C. Combescure The favorable price evolution between bare metal stents and drug eluting stents increases the cost effectiveness of drug eluting stents Int J Cardiol 2013 S0167-5273(12)01683-X http://dx.doi.org/10.1016/j.ijcard.2012.12.054